(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 September 2011 (22.09.2011)

PCT

(10) International Publication Number
WO 2011/114224 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 9/48* (2006.01)
A61K 38/46 (2006.01) *A61P 1/14* (2006.01)
A61K 9/16 (2006.01) *A61J 3/00* (2006.01)
A61K 9/24 (2006.01)

(21) International Application Number:
PCT/IB2011/000579

(22) International Filing Date:
18 March 2011 (18.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/315,814 19 March 2010 (19.03.2010) US

(71) Applicant *(for all designated States except US)*: **AXCAN PHARMA INC.** [CA/CA]; 597 Laurier Boulevard, Mont-Saint-Hilaire, Quebec J3H 6CH (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MATEESCU, Mircea, Alexandru** [CA/CA]; c/o Axcan Pharma Inc., 597 Laurier Boulevard, Mont-Saint-Hilaire, Quebec J3H 6CH (CA). **BUSTOS, Ingry, Janet** [CA/CA]; c/o Axcan Pharma Inc., 597 Laurier Boulevard, Mont-Saint-Hilaire, Quebec J3H 6CH (CA). **DUMOULIN, Yves** [CA/CA]; c/o Axcan Pharma Inc., 597 Laurier Boulevard, Mont-Saint-Hilaire, Quebec J3H 6CH (CA). **SZABO, Pompilia, Ispas** [CA/CA]; c/o Axcan Pharma Inc., 597 Laurier Boulevard, Mont-Saint-Hilaire, Quebec J3H 6CH (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: GASTRO-RESISTANT ENZYME PHARMACEUTICAL COMPOSITIONS

(57) Abstract: The present invention generally relates to compacted pharmaceutical compositions (such as tablets) comprising one or more enzymes, where the composition is monolithic or multiparticulates (such as mini-tablets, micro-tablets, or prills), or where the composition has multiple layers with the outermost layer containing one or more enzymes.




Fig. 1: Cross-section of an excipient-free PEC tablet after incubation in simulated gastric fluid




Fig. 2: Hydration kinetics of excipient-free tablets obtained by direct compression (different tablet size and compression force were used as per Table XII)

WO 2011/114224 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*